Edition:
United Kingdom

ADMA Biologics Inc (ADMA.OQ)

ADMA.OQ on NASDAQ Stock Exchange Capital Market

3.89USD
16 Feb 2018
Change (% chg)

$-0.05 (-1.27%)
Prev Close
$3.94
Open
$3.95
Day's High
$3.96
Day's Low
$3.86
Volume
10,072
Avg. Vol
39,784
52-wk High
$5.44
52-wk Low
$2.02

Chart for

About

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments... (more)

Overall

Beta: 2.10
Market Cap(Mil.): $82.28
Shares Outstanding(Mil.): 25.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-ADMA Files Biologics License Application For Its Third Plasma Collection Center

* ADMA FILES BIOLOGICS LICENSE APPLICATION FOR ITS THIRD PLASMA COLLECTION CENTER

11 Dec 2017

BRIEF-Adma Biologics prices follow-on offering of 17.0 mln shares

* Adma Biologics Inc - ‍pricing of offering of approximately 17.0 million shares of its common stock at price of $2.15 per share​ Source text for Eikon: Further company coverage:

09 Nov 2017

BRIEF-ADMA Biologics now sees offering‍​ of 13.6 mln shares of common stock - SEC filing

* Now sees offering‍​ of 13.6 million shares of its common stock, up from previous filing of 10.2 million shares - SEC filing Source text: (http://bit.ly/2zmNV1L) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

08 Nov 2017

BRIEF-ADMA Biologics Q3 loss per share $0.59

* ADMA Biologics provides corporate update and reports third quarter 2017 financial results

03 Nov 2017

BRIEF-ADMA Biologics says ‍loss per share was $0.59 for fiscal quarter ended Sept 30​

* ADMA Biologics Inc says ‍for fiscal quarter ended September 30, loss per share was $0.59 - SEC filing​

03 Nov 2017

BRIEF-Adma Biologics Inc files for offering of up to $28.75‍​ million of common stock

* Adma Biologics Inc files for offering of up to $28.75‍​ million of common stock Source text: (http://bit.ly/2gvC2f8) Further company coverage:

11 Oct 2017

BRIEF-ADMA Biologics ‍enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset Management​

* ADMA Biologics Inc - ‍entered into a credit agreement for up to $40 million with affiliated entities of marathon asset management​

11 Oct 2017

Competitors

  Price Chg
Baxter International Inc (BAX.N) $66.33 -0.11
Biotest AG (BIOG.DE) €30.80 --
Biotest AG (BIOG_p.DE) €27.25 -0.35

Earnings vs. Estimates